197 related articles for article (PubMed ID: 25257509)
1. Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.
Brennan RC; Furman W; Mao S; Wu J; Turner DC; Stewart CF; Santana V; McGregor LM
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1191-8. PubMed ID: 25257509
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
Furman WL; Navid F; Daw NC; McCarville MB; McGregor LM; Spunt SL; Rodriguez-Galindo C; Panetta JC; Crews KR; Wu J; Gajjar AJ; Houghton PJ; Santana VM; Stewart CF
J Clin Oncol; 2009 Sep; 27(27):4599-604. PubMed ID: 19687340
[TBL] [Abstract][Full Text] [Related]
3. Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.
McGregor LM; Stewart CF; Crews KR; Tagen M; Wozniak A; Wu J; McCarville MB; Navid F; Santana VM; Houghton PJ; Furman WL; Rodriguez-Galindo C
Pediatr Blood Cancer; 2012 Mar; 58(3):372-9. PubMed ID: 21509928
[TBL] [Abstract][Full Text] [Related]
4. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
Wagner LM; Crews KR; Iacono LC; Houghton PJ; Fuller CE; McCarville MB; Goldsby RE; Albritton K; Stewart CF; Santana VM
Clin Cancer Res; 2004 Feb; 10(3):840-8. PubMed ID: 14871959
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J
Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900
[TBL] [Abstract][Full Text] [Related]
7. A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.
Furman WL; McGregor LM; McCarville MB; Onciu M; Davidoff AM; Kovach S; Hawkins D; McPherson V; Houghton PJ; Billups CA; Wu J; Stewart CF; Santana VM
Invest New Drugs; 2012 Aug; 30(4):1660-70. PubMed ID: 21796439
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors.
Levy AS; Meyers PA; Wexler LH; Jakacki R; Angiolillo A; Ringuette SN; Cohen MB; Gorlick R
Cancer; 2009 Jan; 115(1):207-16. PubMed ID: 19090012
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
Wagner LM; Perentesis JP; Reid JM; Ames MM; Safgren SL; Nelson MD; Ingle AM; Blaney SM; Adamson PC
Pediatr Blood Cancer; 2010 Apr; 54(4):538-45. PubMed ID: 20049936
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
Souid AK; Dubowy RL; Blaney SM; Hershon L; Sullivan J; McLeod WD; Bernstein ML
Clin Cancer Res; 2003 Feb; 9(2):703-10. PubMed ID: 12576438
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study.
McGregor LM; Spunt SL; Furman WL; Stewart CF; Schaiquevich P; Krailo MD; Speights R; Ivy P; Adamson PC; Blaney SM
Cancer; 2009 Apr; 115(8):1765-75. PubMed ID: 19170226
[TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.
Fakih MG; Pendyala L; Smith PF; Creaven PJ; Reid ME; Badmaev V; Azrak RG; Prey JD; Lawrence D; Rustum YM
Clin Cancer Res; 2006 Feb; 12(4):1237-44. PubMed ID: 16489079
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.
Horiike A; Kudo K; Miyauchi E; Ohyanagi F; Kasahara K; Horai T; Nishio M
Br J Cancer; 2011 Oct; 105(8):1131-6. PubMed ID: 21915126
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.
Trippett TM; Herzog C; Whitlock JA; Wolff J; Kuttesch J; Bagatell R; Hunger SP; Boklan J; Smith AA; Arceci RJ; Katzenstein HM; Harbison C; Zhou X; Lu H; Langer C; Weber M; Gore L
J Clin Oncol; 2009 Oct; 27(30):5102-8. PubMed ID: 19770383
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).
Hartmann JT; Pintoffl JP; Kröning H; Bokemeyer C; Holtmann M; Höhler T
Onkologie; 2008 May; 31(5):237-41. PubMed ID: 18497512
[TBL] [Abstract][Full Text] [Related]
16. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
Wagner LM; Villablanca JG; Stewart CF; Crews KR; Groshen S; Reynolds CP; Park JR; Maris JM; Hawkins RA; Daldrup-Link HE; Jackson HA; Matthay KK
J Clin Oncol; 2009 Mar; 27(8):1290-6. PubMed ID: 19171709
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of irinotecan in pediatric patients with malignant solid tumors.
Mugishima H; Matsunaga T; Yagi K; Asami K; Mimaya J; Suita S; Kishimoto T; Sawada T; Tsuchida Y; Kaneko M
J Pediatr Hematol Oncol; 2002 Feb; 24(2):94-100. PubMed ID: 11990713
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Metts JL; Trucco M; Weiser DA; Thompson P; Sandler E; Smith T; Crimella J; Sansil S; Thapa R; Fridley BL; Llosa N; Badgett T; Gorlick R; Reed D; Gill J
Cancer Med; 2023 Feb; 12(4):4270-4281. PubMed ID: 36151773
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.
Chau I; Cunningham D; Hickish T; Massey A; Higgins L; Osborne R; Botwood N; Swaisland A
Ann Oncol; 2007 Apr; 18(4):730-7. PubMed ID: 17237473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]